 Eagle Pharmaceuticals, Inc. Nasdaq: EGRX Eagle or the Company today announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimers Disease.1 The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimers disease. Eagle markets a formulation of dantrolene sodium but did not sponsor the study. 